MedTrace Logo

A Phase II Trial of CyberKnife Stereotactic Radiosurgery to Prostate Tumors

NCT02225262 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2019-07-24

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of CyberKnife radiosurgery in patients with early stage prostate cancer.

The investigators hypothesize that hypofractionated stereotactic radiotherapy via the CyberKnife® can deliver tumor ablating doses of radiation to prostate tumors safely and effectively while sparing the adjacent tissues (rectum, bladder, ureters, urethra, penile bulb, and bowel) from receiving damaging doses of radiation.

Conditions

Interventions

RADIATION

CyberKnife Radiosurgery

36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction

Sponsors & Collaborators

  • Community Cancer Center, Normal, Illinois

    lead OTHER

Principal Investigators

  • Shermian Woodhouse, MD · Community Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2020-01-31
Completion
2020-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02225262 on ClinicalTrials.gov